首页 /药靶模型 /药靶细胞 /免疫治疗 /CD86/CHO

CD86/CHO

CBP74070

询 价
索取Protocol
产品描述
产品数据库
I. Background
B7-2 (CD86) signaling through CTLA4 (CD152) has been shown to inhibit T- cell activation. This co-inhibitory pathway can be overactive in many tumors, enabling cancers to escape the host’s immune system. CTLA4-blocking antibodies, including Ipilimumab (Yervoy) and Tremelimumab, have shown clinical efficacy in treating cancer.
 
II. Description

Recombinant CHO cells constitutively expressing human CD86.

 
III. Introduction
Host Cell: CHO
Expressed gene: CD86
Stability: 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)
Synonym(s):

T-lymphocyte activation antigen CD86, B7.2, FUN-1, B70, BU63, CD86, B72

Freeze Medium: 90% FBS+10% DMSO
Culture Medium: F12K+10%FBS+500ug/ml hygromycin
Mycoplasma Testing: Negative
Storage: Liquid nitrogen
Application(s): Ligand of CD28&Binding Assay,FACS
 
IV. Description of Host Cell Line
Organism: Cricetulus griseus, hamster, Chinese
Tissue: Ovary
Disease: Hamster Chinese ovary
Morphology: Epitheloid cell
Growth Properties: Adherent
 
Ⅴ. Representative Data

Figure 1. Recombinant CHO cells expressing human CD86.

 

药靶模型联系方式: 华东销售经理:18240630236 全国销售经理:18066071954
诊断标准品联系方式: 华东销售经理:15000320447 华北销售经理:18131625521 华南销售经理:13484295986 华中&西南销售经理:13871580511 全国销售经理:13484295986

扫二维码

立即提交